Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
The Lancet. Oncology
|
September 10, 2002
Overhauling the breast cancer overview: are subsets subversive?
Alan Coates, Aron Goldhirsch, Richard Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Reply to D. Serraino et al
Ann H Partridge, Shari Gelber, Richard Gelber
Biostatistics (Oxford, England)
|
January 24, 2006
Estimation in regression models for longitudinal binary data with outcome-dependent follow-up
Garrett M Fitzmaurice, Stuart R Lipsitz, Joseph G Ibrahim, et al.
Biometrics
|
September 17, 2002
Parameter estimation in longitudinal studies with outcome-dependent follow-up
Stuart R Lipsitz, Garrett M Fitzmaurice, Joseph G Ibrahim, et al.
Breast Cancer Research and Treatment
|
June 24, 2011
Pregnancy after breast cancer: if you wish, ma'am
Olivia Pagani, Ann Partridge, Larissa Korde, et al.
The Lancet. Oncology
|
August 14, 2018
Sex as a predictor of response to cancer immunotherapy - Authors' reply
Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
European Urology
|
September 19, 2018
Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium
Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2004
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93
, Olivia Pagani, Shari Gelber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2026
"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"
Fabio Conforti, Isabella Sala, Laura Pala, et al.
The Pediatric Infectious Disease Journal
|
September 28, 2002
Concentrations of protease inhibitors in cord blood after in utero exposure
Mark Mirochnick, Alex Dorenbaum, Diane Holland, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
The Lancet. Oncology
|
September 10, 2002
Overhauling the breast cancer overview: are subsets subversive?
Alan Coates, Aron Goldhirsch, Richard Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Reply to D. Serraino et al
Ann H Partridge, Shari Gelber, Richard Gelber
Biostatistics (Oxford, England)
|
January 24, 2006
Estimation in regression models for longitudinal binary data with outcome-dependent follow-up
Garrett M Fitzmaurice, Stuart R Lipsitz, Joseph G Ibrahim, et al.
Biometrics
|
September 17, 2002
Parameter estimation in longitudinal studies with outcome-dependent follow-up
Stuart R Lipsitz, Garrett M Fitzmaurice, Joseph G Ibrahim, et al.
Breast Cancer Research and Treatment
|
June 24, 2011
Pregnancy after breast cancer: if you wish, ma'am
Olivia Pagani, Ann Partridge, Larissa Korde, et al.
The Lancet. Oncology
|
August 14, 2018
Sex as a predictor of response to cancer immunotherapy - Authors' reply
Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
European Urology
|
September 19, 2018
Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium
Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2004
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93
, Olivia Pagani, Shari Gelber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2026
"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"
Fabio Conforti, Isabella Sala, Laura Pala, et al.
The Pediatric Infectious Disease Journal
|
September 28, 2002
Concentrations of protease inhibitors in cord blood after in utero exposure
Mark Mirochnick, Alex Dorenbaum, Diane Holland, et al.
Page
of 2